Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	16,912	17,300	16,892	16,259	17,018
Revenue Growth (YoY)	-3.33%	2.42%	3.90%	-4.46%	-
Cost of Revenue	7,415	7,575	7,000	6,511	6,709
Gross Profit	9,496	9,726	9,892	9,747	10,309
Selling, General & Admin	10,042	9,630	8,770	10,294	10,496
Other Operating Expenses	231.36	226.31	202.89	233.72	232.08
Operating Expenses	11,189	10,755	9,652	10,876	11,251
Operating Income	-1,693	-1,030	240.28	-1,129	-942.29
Interest Expense	-37.24	-37.89	-50.74	-123.43	-141.38
Interest & Investment Income	445.94	479.1	483.95	235.26	23.31
Currency Exchange Gain (Loss)	-4.99	-2.49	-	-	-
Other Non Operating Income (Expenses)	2.93	-4.44	-2.55	1,034	-710.32
EBT Excluding Unusual Items	-1,286	-595.32	670.94	17.23	-1,771
Gain (Loss) on Sale of Investments	-	-	-	-	119.95
Gain (Loss) on Sale of Assets	-2.84	-5.35	80.91	-51.74	0.4
Asset Writedown	-	-	-18.82	-	-372.94
Pretax Income	-1,289	-600.67	733.03	-34.51	-2,023
Income Tax Expense	-	-	-	11.53	-
Earnings From Continuing Operations	-1,289	-600.67	733.03	-46.04	-2,023
Earnings From Discontinued Operations	-	-	-	-	1,277
Net Income to Company	-1,289	-600.67	733.03	-46.04	-746.02
Minority Interest in Earnings	-	-	-	-	30.28
Net Income	-1,289	-600.67	733.03	-46.04	-715.74
Net Income to Common	-1,289	-600.67	733.03	-46.04	-715.74
Shares Outstanding (Basic)	32	32	32	29	25
Shares Outstanding (Diluted)	32	32	32	29	25
Shares Change (YoY)	-1.33%	-1.33%	10.57%	14.11%	-
EPS (Basic)	-40.65	-18.94	22.81	-1.58	-28.10
EPS (Diluted)	-40.82	-19.00	22.81	-2.00	-28.86
Free Cash Flow	-60.28	27.73	1,586	-45.94	-403.57
Free Cash Flow Per Share	-1.90	0.88	49.34	-1.58	-15.84
Gross Margin	56.15%	56.22%	58.56%	59.95%	60.58%
Operating Margin	-10.01%	-5.95%	1.42%	-6.94%	-5.54%
Profit Margin	-7.62%	-3.47%	4.34%	-0.28%	-4.21%
Free Cash Flow Margin	-0.36%	0.16%	9.39%	-0.28%	-2.37%
EBITDA	-1,001	-355.15	919.37	-627.62	-403.04
EBITDA Margin	-5.92%	-2.05%	5.44%	-3.86%	-2.37%
D&A For EBITDA	692.25	674.45	679.09	500.9	539.25
EBIT	-1,693	-1,030	240.28	-1,129	-942.29
EBIT Margin	-10.01%	-5.95%	1.42%	-6.94%	-5.54%
Advertising Expenses	-	10.37	59.51	337.74	119.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.